Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response
Retrieved on:
Tuesday, December 14, 2021
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Science, Clinical Trials, TRRAP, Personalized medicine, Clinical trial, MDS, Abstract, AZA, Disease, CBM, Drug resistance, Antigen, Biosimulation, HMA, Biomarker, Artificial intelligence, Myelodysplastic syndrome, CAV1, DAC, KDM4C, IFNA1, JAK2, MD, ASH, Society, Monosomy, Group, HIPK2, Research, Exposition, Agilent Technologies, DNA, VPA, HDAC, Software, Drug combination, Sequoia Capital, GSK3B, CD8, CTNNB1, Immunology, Azacitidine, UnitedHealth Group, Escape Room, Neoplasm, Patient, CD274, Medical device, Vaccine, Pharmaceutical industry, Decitabine
In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.
Key Points:
- In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.
- The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
- Cellworks Biosimulation Platform found that signaling pathway consequences related to CTNNB1 and c-MYC modulation predict response to DAC + VPA.
- Biosimulation using the Cellworks Computational Omics Biology Model (CBM) identifies immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.